Develops and sells ZUNVEYL, an oral treatment for Alzheimer’s disease, to wholesalers and pharmacies, while developing other treatments for neurodegenerative diseases.
10-K for FY2025, filed Mar 31, 2026We are a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as…View ↗
We launched ZUNVEYL on March 19, 2025 and will target the largest volume nursing homes specializing in Alzheimer’s Disease, leveraging an…View ↗
Products are primarily sold to direct customers such as wholesalers and pharmacies. The Company’s contractual performance obligations are…View ↗
Wholesalers and pharmacies pay for ZUNVEYL when it is delivered. Licensing income comes from upfront payments, development or sales milestones, royalties, and sales of ingredients or finished goods to a partner.
10-K for FY2025, filed Mar 31, 2026Product revenue consists primarily of sales of the Company’s commercial product to wholesalers and pharmacies. Revenue is recognized at a…View ↗
License revenue consists of revenue from our License, Collaboration and Distribution Agreement with CMS International Development and…View ↗
Our revenue to date has been generated primarily from the upfront payment received from CMSI under the CMSI License Agreement. In addition…View ↗
License revenue also includes revenue from the sale of API and finished goods to CMSI, which are generally priced at cost plus a margin, as…View ↗
Products are primarily sold to direct customers such as wholesalers and pharmacies. The Company’s contractual performance obligations are…View ↗
10-K for FY2025, filed Mar 31, 2026
FY2025 revenue by product or service ↗$10.2M
10-K for FY2025, filed Mar 31, 2026
$10.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product, net
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
66% |
Product, net, FY2025
$6.8M Sources
|
Sold outright |
|
Licensing
|
34% |
Licensing, FY2025
$3.4M Sources
|
Wholesalers and pharmacies buy ZUNVEYL directly; the company also works with a licensing and distribution partner for sales in parts of Asia, Australia and New Zealand.
10-K for FY2025, filed Mar 31, 2026
10-K for FY2025, filed Mar 31, 2026
The Company considers its significant customers to be those that represent more than 10% of total revenue or accounts receivable. As of and…View ↗
No. It lost $20.7M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$7.6MView ↗
10-Q for Q3 FY2026, filed Nov 12, 2026
Open tableView ↗
8-K, filed Apr 14, 2026
On April 10, 2026, Alpha Cognition Inc. (the “Company”) entered into a settlement agreement and mutual release (the “Early Settlement…View ↗
Competes with Eisai, Pfizer, Novartis, Janssen, Corium, and Biogen
10-K for FY2025, filed Mar 31, 2026Donepezil (marketed under the brand name, Aricept by Eisai and Pfizer)View ↗
Loading...